Outcome and impact of post-remission strategy after MIDAM regimen in patients with relapsing or refractory acute myeloid leukemia - Role of intra-Clonal HEterogeneity and Leukemic environment in ThErapy Resistance of chronic leukemias Accéder directement au contenu
Article Dans Une Revue American Journal of Hematology Année : 2019

Outcome and impact of post-remission strategy after MIDAM regimen in patients with relapsing or refractory acute myeloid leukemia

Dates et versions

hal-01926811 , version 1 (19-11-2018)

Identifiants

Citer

Salem Bahashwan, Cécile Moluçon-Chabrot, Eric Hermet, Aurélie Ravinet, Aurore Douge, et al.. Outcome and impact of post-remission strategy after MIDAM regimen in patients with relapsing or refractory acute myeloid leukemia. American Journal of Hematology, 2019, 94 (1), pp.E32-E35. ⟨10.1002/ajh.25332⟩. ⟨hal-01926811⟩
58 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More